Safety of turoctocog alfa for prophylaxis and treatment of bleeding episodes in previously treated patients with moderate or severe Haemophilia A in India.

Trial Profile

Safety of turoctocog alfa for prophylaxis and treatment of bleeding episodes in previously treated patients with moderate or severe Haemophilia A in India.

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 07 Sep 2018

At a glance

  • Drugs Turoctocog alfa (Primary)
  • Indications Haemophilia A
  • Focus Therapeutic Use
  • Acronyms guardian TM 10
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 02 Mar 2018 Status changed from not stated to recruiting.
    • 22 Feb 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top